# Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM

Study · id `cardio:ct-nct02266030` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02266030](<https://clinicaltrials.gov/study/NCT02266030>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02266030

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02266030. Randomized; no masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2016-11 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02266030, source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)
- Start date: 2011-02 (registry gives no type) (ClinicalTrials.gov record NCT02266030, source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)
- Primary completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02266030, source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)
- Completion: 2016-11 (actual) (ClinicalTrials.gov record NCT02266030, source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT02266030, source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02266030-2017-10-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM
- Acronym: ESCAPE
- Condition: Coronary Artery Disease
- Intervention (Drug): Cilostazol
- Intervention (Drug): Aspirin
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: 3da0977254bfaf7bdd2140c842db408544c13211b7b7d06eda4df654ff709be2
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
